Basal cell carcinoma - Karċinoma Taċ-Ċelloli Bażali
☆ Fir-riżultati ta' Stiftung Warentest tal-2022 mill-Ġermanja, is-sodisfazzjon tal-konsumatur b'ModelDerm kien biss ftit inqas milli b'konsultazzjonijiet bit-telemediċina mħallsa.
Leżjonijiet ulċerati li jaffettwaw il-ġilda ta 'l-imnieħer f'individwu anzjan huma spiss iddijanjostikati bħala Karċinoma Taċ-Ċelloli Bażali (Basal cell carcinoma). L-imnieħer huwa sit komuni ta 'okkorrenza għal dan it-tip ta' kanċer tal-ġilda.
Karċinoma Taċ-Ċelloli Bażali (Basal cell carcinoma) jistgħu jippreżentaw fruntieri u ulċeri irregolari.
Karċinoma Taċ-Ċelloli Bażali (Basal cell carcinoma) jistgħu jiġu żbaljati għal felul.
References
Basal cell carcinoma (BCC) huwa l-aktar tip komuni ta’ kanċer tal-ġilda. L-espożizzjoni għad-dawl tax-xemx hija l-kawża ewlenija. Kważi l-każijiet kollha BCC juru sinjalazzjoni Hedgehog attiva żżejjed fl-analiżi molekulari. Trattamenti differenti huma disponibbli u magħżula abbażi tar-riskju ta 'rikorrenza, l-importanza tal-preservazzjoni tat-tessuti, il-preferenza tal-pazjent, u l-firxa tal-marda.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas huma l-aktar tip komuni ta' kanċer tal-ġilda f'adulti ta' ġilda ċara ta' 50 sena 'l fuq. In-numru tagħhom qed jiżdied mad-dinja kollha, l-aktar minħabba l-espożizzjoni għad-dawl tax-xemx. Ċerti kundizzjonijiet ġenetiċi jistgħu jagħmlu lin-nies suxxettibbli li jiżviluppaw dawn il-kanċer f'età iżgħar. Basal cell carcinomas ivarjaw fis-severità, li jvarjaw minn leżjonijiet superfiċjali jew nodulari li jistgħu jiġu kkurati faċilment għal dawk aktar estensivi li jeħtieġu diskussjoni f'timijiet mediċi speċjalizzati. Il-pronjosi tiddependi fuq il-probabbiltà li l-kanċer jerġa 'lura jew il-kapaċità tiegħu li jagħmel ħsara lit-tessut fil-qrib. Il-kirurġija hija t-trattament standard għal ħafna mill-każijiet, li tiżgura tneħħija preċiża u ċansijiet baxxi ta 'rikorrenza. Metodi inqas invażivi jistgħu jittrattaw b'mod effettiv leżjonijiet superfiċjali.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
It-trattament primarju għal BCC huwa kirurġija. Għal BCC ta 'riskju għoli jew rikorrenti, speċjalment f'żoni kritiċi, kirurġija kkontrollata mikrografikament hija rakkomandata. Pazjenti b'BCC superfiċjali ta' riskju baxx jistgħu jikkunsidraw trattamenti topiċi jew metodi distruttivi. It-terapija fotodinamika taħdem tajjeb għal BCCs nodulari superfiċjali u ta 'riskju baxx. Għal BCC lokalment avvanzat jew metastatiku, inibituri Hedgehog (vismodegib, sonidegib) huma rakkomandati. Jekk ikun hemm progressjoni tal-marda jew intolleranza għall-inibituri Hedgehog, tista' tiġi kkunsidrata immunoterapija b' anti-PD1 antibody (cemiplimab) . Ir-radjuterapija hija għażla tajba għal pazjenti li ma jistgħux jagħmlu kirurġija, speċjalment pazjenti anzjani. L-elettrokimoterapija tista' tiġi kkunsidrata jekk il-kirurġija jew ir-radjuterapija ma tkunx għażla.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Fatturi ta’ riskju jinkludu espożizzjoni għad-dawl ultravjola, terapija bir-radjazzjoni, espożizzjoni fit-tul għall-arseniku u funzjoni ħażina tas-sistema immuni (eż. trapjant ta’ organi). L-espożizzjoni għad-dawl UV matul it-tfulija hija partikolarment ta 'ħsara.
Wara d-dijanjosi permezz ta 'bijopsija, it-trattament huwa tipikament permezz ta' tneħħija kirurġika. Dan jista’ jsir b’sempliċi qtugħ jekk il-kanċer ikun żgħir; Jekk il-kanċer mhuwiex żgħir, il-kirurġija ta 'Mohs hija ġeneralment rakkomandata.
Karċinoma taċ-ċelluli bażali tammonta għal mill-inqas 32% tal-kanċers kollha globalment. Mill-kanċer tal-ġilda minbarra l-melanoma, madwar 80% huma kanċers taċ-ċelluli bażali. Fl-Istati Uniti, madwar 35% tal-irġiel bojod u 25% tan-nisa bojod huma affettwati minn karċinoma taċ-ċelluli bażali f'xi punt f'ħajjithom.
○ Djanjosi u Trattament
#Dermoscopy
#Skin biopsy
#Mohs surgery